[1] CARLANDER AF,GRONHOJ LC,JENSEN DH,et al.Continuing rise in oropharyngeal cancer in a high HPV prevalence area:A Danish population-based study from 2011 to 2014［J］.Eur J Cancer,2017,70:75-82.
[2] TABERNA M,MENA M,PAVON MA,et al.Human papillomavirus-related oropharyngeal cancer［J］.Ann Oncol,2017,28(10):2386-2398.
[3] BRAVO IG,FELEZ-SANCHEZ M.Papillomaviruses:Viral evolution,cancer and evolutionary medicine［J］.Evol Med Public Health,2015,2015(1):32-51.
[4] OROSZ E,GOMBOS K,PETREVSZKY N,et al.Visualization of mucosal field in HPV positive and negative oropharyngeal squamous cell carcinomas:combined genomic and radiology based 3D model［J］.Sci Rep,2020,10(1):40.
[5] VOJTECHOVA Z,ZAVADIL J,KLOZAR J,et al.Comparison of the miRNA expression profiles in fresh frozen and formalin-fixed paraffin-embedded tonsillar tumors［J］.PLoS One,2017,12(6):e179645.
[6] WURLITZER M,MOECKELMANN N,KRIEGS M,et al.Mass spectrometric comparison of HPV-positive and HPV-negative oropharyngeal cancer［J］.Cancers,2020,12(6):1531.
[7] D'SOUZA G,MCNEEL TS,FAKHRY C.Understanding personal risk of oropharyngeal cancer:risk-groups for oncogenic oral HPV infection and oropharyngeal cancer［J］.Ann Oncol,2017,28(12):3065-3069.
[8] ANANTHARAMAN D,ABEDI-ARDEKANI B,BEACHLER DC,et al.Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer［J］.Int J Cancer,2017,140(9):1968-1975.
[9] JEMAL A,SIMARD EP,DORELL C,et al.Annual report to the nation on the status of cancer,1975-2009,featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels［J］.J Natl Cancer Inst,2013,105(3):175-201.
[10] TIMBANG MR,SIM MW,BEWLEY AF,et al.HPV-related oropharyngeal cancer:a review on burden of the disease and opportunities for prevention and early detection［J］.Hum Vaccin Immunother,2019,15(7-8):1920-1928.
[11] LIU J,YANG XL,ZHANG SW,et al.Incidence,mortality,and temporal patterns of oropharyngeal cancer in China:a population-based study［J］.Cancer Commun(Lond),2018,38(1):75.
[12] DICKINSON A,SARASWAT M,SYRJANEN S,et al.Comparing serum protein levels can aid in differentiating HPV-negative and-positive oropharyngeal squamous cell carcinoma patients［J］.PLoS One,2020,15(6):e233974.
[13] CHERA BS,KUMAR S,SHEN C,et al.Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer［J］.J Clin Oncol,2020,38(10):1050-1058.
[14] KREIMER AR,FERREIRO-IGLESIAS A,NYGARD M,et al.Timing of HPV16-E6 antibody seroconversion before OPSCC:findings from the HPVC3 consortium［J］.Ann Oncol,2019,30(8):1335-1343.
[15] MENA M,TABERNA M,TOUS S,et al.Double positivity for HPV-DNA/p16(ink4a)is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients［J］.Oral Oncol,2018,78:137-144.
[16] BALACHANDRA S,KUSIN SB,LEE R,et al.Blood-based biomarkers of human papillomavirus-associated cancers:A systematic review and meta-analysis［J］.Cancer,2021,127(6):850-864.
[17] WESTRICH JA,VERMEER DW,SILVA A,et al.CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8(+)T-cell responses by upregulating MHC-I expression［J］.Oncogene,2019,38(46):7166-7180.
[18] ZHANG S,WANG B,MA F,et al.Characteristics of B lymphocyte infiltration in HPV(+)head and neck squamous cell carcinoma［J］.Cancer Sci,2021,112(4):1402-1416.
[19] HLADIKOVA K,KOUCKY V,BOUCEK J,et al.Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+)T cells［J］.J Immunother Cancer,2019,7(1):261.
[20] KOMDEUR FL,PRINS TM,VAN DE WALL S,et al.CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer［J］.Oncoimmunology,2017,6(9):e1338230.
[21] SOLOMON B,YOUNG RJ,BRESSEL M,et al.Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance［J］.Ann Oncol,2019,30(10):1638-1646.
[22] MIRGHANI H,AMEN F,MOREAU F,et al.Human papilloma virus testing in oropharyngeal squamous cell carcinoma:what the clinician should know［J］.Oral Oncol,2014,50(1):1-9.
[23] PRIGGE ES,ARBYN M,VON KNEBEL DM,et al.Diagnostic accuracy of p16(INK4a)immunohistochemistry in oropharyngeal squamous cell carcinomas:A systematic review and meta-analysis［J］.Int J Cancer,2017,140(5):1186-1198.
[24] GILLISON ML,TROTTI AM,HARRIS J,et al.Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer(NRG Oncology RTOG 1016):a randomised,multicentre,non-inferiority trial［J］.LANCET,2019,393(10166):40-50.
[25] ANG KK,ZHANG Q,ROSENTHAL DI,et al.Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage Ⅲ to Ⅳ head and neck carcinoma:RTOG 0522［J］.J Clin Oncol,2014,32(27):2940-2950.
[26] CHEN AM,FELIX C,WANG PC,et al.Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx:a single-arm,phase 2 study［J］.Lancet Oncol,2017,18(6):803-811.
[27] CRACCHIOLO JR,BAXI SS,MORRIS LG,et al.Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features:National Cancer Data Base［J］.Cancer,2016,122(10):1523-1532.
[28] DE ALMEIDA JR,LI R,MAGNUSON JS,et al.Oncologic outcomes after transoral robotic surgery:a multi-institutional study［J］.JAMA Otolaryngol Head Neck Surg,2015,141(12):1043-1051.
[29] CHIA SH,GROSS ND,RICHMON JD.Surgeon experience and complications with transoral robotic surgery(TORS)［J］.Otolaryngol Head Neck Surg,2013,149(6):885-892.
[30] FAKHRY C,ZHANG Q,NGUYEN-TAN PF,et al.Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer［J］.J Clin Oncol,2017,35(36):4057-4065.
[31] ZHAN KY,PURAM SV,LI MM,et al.National treatment trends in human papillomavirus-positive oropharyngeal squamous cell carcinoma［J］.Cancer,2020,126(6):1295-1305.
[32] FUNG N,FARAJI F,KANG H,et al.The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma［J］.Cancer Metastasis Rev,2017,36(3):449-461.
[33] SANCHEZ-CANTELI M,GRANDA-DIAZ R,DEL RN,et al.PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas［J］.Cancer Immunol Immunother,2020,69(10):2089-2100.
[34] YOUNG RJ,BRESSEL M,PORCEDDU S,et al.Validation and characterisation of prognostically significant PD-L1(+)immune cells in HPV+ oropharyngeal squamous cell carcinoma［J］.Oral Oncol,2020,101:104516.
[35] WELTERS M,MA W,SANTEGOETS S,et al.Intratumoral HPV16 specific T cells constitute a type Ⅰ-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer［J］.Clin Cancer Res,2018,24(3):634-647.
[36] LEHTINEN M,DILLNER J.Clinical trials of human papillomavirus vaccines and beyond［J］.Nat Rev Clin Oncol,2013,10(7):400-410.
[37] STANLEY M,PINTO LA,TRIMBLE C.Human papillomavirus vaccines-immune responses［J］.Vaccine,2012,30(5):F83-F87.
[38] MARKOWITZ LE,NALEWAY AL,KLEIN NP,et al.Human papillomavirus vaccine effectiveness against HPV infection:evaluation of one,two,and three doses［J］.J Infect Dis,2020,221(6):910-918.